苏格兰批准新的CAR T细胞疗法, 治疗具有攻击性的血液癌, 提高存活率。 Scotland approves new CAR T-cell therapy Yescarta for aggressive blood cancers, offering improved survival rates.

苏格兰医药联合会(SMC)已经批准了Yescarta(axi-cel),这是CAR T细胞疗法,用于治疗具有攻击性的血癌,如DLBCL和HGBL,标志着首次批准在苏格兰进行二线治疗。 The Scottish Medicines Consortium (SMC) has approved Yescarta (axi-cel), a CAR T-cell therapy, for treating aggressive blood cancers like DLBCL and HGBL, marking its first approval for second-line treatment in Scotland. 此前的临床试验表明,存活率高于标准治疗。 This follows clinical trials showing improved survival rates over standard treatments. 此外,用于AML的quizartinib (Vanflyta) 也已获得批准,为患有这些癌症的患者提供了新的希望. Additionally, quizartinib (Vanflyta) for AML has also been approved, offering new hope to patients with these cancers.